Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-CD19 chimeric antigen receptor T cell therapy - Takara Bio

Next Previous
Drug Profile

Anti-CD19 chimeric antigen receptor T cell therapy - Takara Bio

Alternative Names: CD19 CAR gene transduced T lymphocytes - Takara Bio; CD19 chimeric antigen receptor T cell therapy - Takara Bio; CD19-CAR gene therapy - Takara Bio; CD19-CAR T cell therapy - Takara Bio; TBI-1501

Latest Information Update: 17 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Jichi Medical School; Otsuka Pharmaceutical; Takara Bio
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 09 Nov 2021 Otsuka Pharmaceutical terminates development and licensing agreement with Takara Bio for anti-CD19 chimeric antigen receptor T cell therapy in Japan
  • 10 Apr 2018 Otsuka Pharmaceutical and Takara Bio agree to co-promote [and co-develop] TBI 1301 in Japan for Cancer
  • 19 May 2017 Takara Bio plans a phase I/II trial for Acute lymphoblastic leukaemia (Second-line therapy or greater) in Japan (NCT03155191)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top